Fate Therapeutics (FATE) vs Inhibikase Therapeutics (IKT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Fate Therapeutics (FATE) has outperformed Inhibikase Therapeutics (IKT) over the past year, gaining 54.7% versus a gain of 19.8%. Over five years, IKT leads with a -83.2% price change compared with -96.5% for FATE. Inhibikase Therapeutics is the larger company by market cap ($270.7 million vs $257.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FATE | IKT |
|---|---|---|
| Share price | $2.15 | $1.94 |
| Market cap | $257.61M | $270.70M |
| 1-day change | -6.11% | -2.02% |
| YTD return | +119.39% | -5.37% |
| 1-year return | +54.68% | +19.75% |
| 5-year return | -96.49% | -83.25% |
| EPS (TTM) | $-0.99 | $-0.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.23 | $2.61 |
| 52-week low | $0.95 | $1.33 |
| Distance from 52-week high | -33.44% | -25.67% |
| Analyst consensus | buy | none |
| Avg. price target upside | +166.98% | +209.28% |
| Average volume | 1.90M | 659.39K |
| Shares outstanding | 119.82M | 139.54M |
| Employees | 161 | 35 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FATE has outperformed IKT by 34.9 percentage points over the past year.
About Fate Therapeutics
FATE stock →Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity.
Healthcare · Biotechnology · 161 employees
About Inhibikase Therapeutics
IKT stock →Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance.
Healthcare · Biotechnology · 35 employees
FATE vs IKT FAQ
Which is bigger, Fate Therapeutics or Inhibikase Therapeutics?
Inhibikase Therapeutics (IKT) is larger, with a market capitalization of $270.70M compared with $257.61M for Fate Therapeutics (FATE).
Which stock has performed better over the past year, FATE or IKT?
FATE returned +54.68% over the past 12 months, compared with +19.75% for IKT (price return, excluding dividends). Past performance does not predict future results.
Are Fate Therapeutics and Inhibikase Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.